Cardio-Immuno-Oncology

The immuno-oncology framework

Developers of cancer immunotherapy have struggled for decades to achieve clinical success in using the patient's immune system to treat cancer. In the absence of a defined development paradigm for immunotherapies, conventional criteria established for chemotherapy were applied to these agents. This article summarizes the recent lessons for development of agents in the immunotherapy space, descr...

Mevalonate Metabolism in Immuno-Oncology

Immuno-oncology not only refers to the multifaceted relationship between our immune system and a developing cancer but also includes therapeutic approaches that harness the body's immune system to fight cancer. The recognition that metabolic reprogramming governs immunity was a key finding with important implications for immuno-oncology. In this review, we want to explore how activation and dif...

Cardio-oncology for the 21st century: introduction.

Cardio-oncology: it takes two to translate.

As an emerging discipline focused on the cardiovascular care of cancer patients, cardio-oncology represents a novel platform for translational investigations. Toxic effects on the heart and vasculature caused by targeted cancer therapies can reveal insights into the biology of cardiovascular disease in humans. This phenomenon was first observed with trastuzumab, a monoclonal antibody that targe...

Cardio-Oncology: mechanisms of cardiovascular toxicity

The therapeutic options available to treat a wide range of malignancies are rapidly increasing. At the same time, the population being treated is aging with more cardiovascular risk factors, comorbid conditions, and associated poor cardiac reserve. Both traditional chemotherapeutic agents (for example, anthracyclines) and newer therapies (for example, targeted tyrosine kinase inhibitors and imm...